BioCity, the incubation specialist with locations in the East Midlands, North West and Scotland has announced a new investment fund, created following a significant contribution by AstraZeneca.
The £5 million fund, to be managed by BioCity will make equity investments, typically between £50,000 and £250,000, in life science companies based at Alderley Park, Cheshire. BioCity Chairman, Dr Louis Nisbet explains: “We are very pleased that AstraZeneca has chosen BioCity to manage these funds, not only to support the growth of a new generation of life science businesses at Alderley Park but also to make sound investment decisions that aim to replenish and grow this evergreen fund over time."